Summary
A large observational analysis published in The Lancet Diabetes & Endocrinology examined more than 98,000 adults with type 2 diabetes and no prior cardiovascular disease. Researchers assessed use of GLP-1 receptor agonists (GLP-1 RAs) together with adherence to healthy lifestyle habits and tracked major adverse cardiovascular events (MACE). Participants who combined GLP-1 RA treatment with multiple healthy habits had the largest reduction in cardiovascular risk compared with those who did neither.
Background
Type 2 diabetes affects tens of millions of people in the United States and is expected to rise over the coming decade. GLP-1 receptor agonists, including widely used agents such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, a dual agonist often grouped with GLP-1s in practice), help control blood glucose by increasing insulin secretion, reducing hepatic glucose production, slowing gastric emptying, suppressing appetite, and promoting weight loss.
Key findings
– The greatest reduction in cardiovascular events was seen in people who used a GLP-1 RA and followed many healthy lifestyle habits.
– Those using a GLP-1 RA and following six to eight healthy habits had a 43% lower risk of MACE compared with people who did not use a GLP-1 RA and followed three or fewer habits.
– Participants adhering to all eight healthy habits had a 60% lower MACE risk than those adhering to one or fewer habits.
– Use of a GLP-1 RA alone (without accounting for lifestyle) was associated with a modest 16% lower risk of MACE versus nonuse.
What the healthy habits were
The study highlighted a cluster of heart-healthy behaviors that appeared to enhance the benefits of therapy: eating a healthy diet, engaging in regular physical activity, getting adequate high-quality sleep, managing stress, avoiding tobacco, limiting excessive alcohol intake, and maintaining social connections. The authors framed lifestyle change as a core element of diabetes care that can amplify the effects of modern medications.
Limitations
This was an observational study, so it cannot prove causation and may be affected by residual confounding, including socioeconomic factors and unmeasured health behaviors. The cohort was drawn largely from a population of predominantly white male veterans, which could limit generalizability, although subgroup analyses reportedly showed consistent patterns across racial, ethnic, and sex groups.
Implications
For clinicians and patients, the findings support combining effective glucose-lowering therapies like GLP-1 RAs with sustained lifestyle improvements to maximize cardiovascular benefit. From a public health perspective, the results underscore the importance of population-level policies and investments that make healthy diets, physical activity, sleep health, stress reduction, and social support more accessible.
Practical takeaways
– Medication and lifestyle appear to be additive: using a GLP-1 RA can lower cardiovascular risk, but the largest gains come when treatment is paired with multiple healthy habits.
– Patients with type 2 diabetes should discuss the risks, benefits, and suitability of GLP-1 RAs with their clinicians while also seeking support for sustainable lifestyle changes.
– Policymakers and health systems should continue to prioritize programs that make healthy living feasible for more people, even as pharmacologic options expand.
Overall, the study reinforces that combining modern therapies with comprehensive lifestyle care offers the best strategy to reduce cardiovascular risk in people with type 2 diabetes, while noting that further research in more diverse populations and randomized settings would strengthen causal inference.
